Trial of CGM Technology in Persons Living With Prediabetes
ConditionPrediabetes
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWake Forest University Health Sciences
About this trial
Continuous glucose monitor (CGM) technology has become increasingly prevalent in the population and has the ability to transform care of patients living with prediabetes. While the technology was initially utilized primarily by patients living with type 1 diabetes using insulin pump therapy, it has become more widely used as part of care in patients living with type 1 or 2 diabetes on any kind of insulin therapy.
Eligibility criteria
Qualifiers
Subjects affiliated with one of the two institutional ambulatory clinics participating in this study who are meeting criteria for prediabetes listed on American Diabetes Association website, which includes A1c = or > than 5.7% and < or = 6.4%, who also have reliable access to a smartphone device compatible with the CGM application
Greater than or equal to 18 years old
Disqualifiers
Subjects who have been diagnosed with type 1 or type 2 diabetes mellitus, as defined as A1c > or = 6.5%
Subjects who do not have reliable access to a smartphone device compatible with the CGM application
Pregnant patients
Trial design
Treatments tested in this trial
- Stelo CGM
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
1Wake Forest University Health Sciences27157, Winston-SalemNorth Carolina, United States
Sponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
Source ClinicalTrials.gov